---
title: Deep Clinical Analysis
category: oncology
summary: >
  Synthesized clinical reasoning addressing whether sigmoid and ileal tumors
  are monocentric or polycentric disease. Analyzes surgical strategy, margins,
  MRD-guided decisions. Identifies 8 clinical gaps and 12 positive prognostic
  indicators with surveillance watch list.
tags:
  - clinical-reasoning
  - treatment-planning
  - diagnostic-certainty
  - stage-IV-disease
  - surgical-oncology
  - margin-analysis
  - MRD-guided-care
  - surveillance-protocol
source: claude
date: "2026-02-15"
status: current
data_snapshot: "2026-02-16"
related_tables:
  - pathology_reports
  - lab_results
  - imaging_reports
  - procedures
  - conditions
  - medications
  - encounters
  - clinical_notes
related_conditions:
  - Adenocarcinoma of sigmoid colon (pT4aN1aM0, Stage IIIB)
  - Adenocarcinoma of terminal ileum (pT4aN2b)
  - Metastatic colorectal cancer to liver (oligometastatic)
  - Peritoneal carcinomatosis
  - Chronic ileitis (possible Crohn's)
  - Hashimoto's thyroiditis
  - Thrombocytopenic disorder
date_range:
  start: "2021-12-29"
  end: "2026-02-16"
key_findings:
  - Evidence favors monocentric origin (sigmoid primary with peritoneal spread)
  - Positive margin on segment 2 liver resection (2025-05-14)
  - Final two liver resections achieved R0 margins
  - 12 positive prognostic indicators identified
  - 8 clinical gaps requiring follow-up
clinical_gaps:
  - Positive margin on segment 2 resection
  - Indeterminate suprahilar lymph node
  - Lung nodules (metastatic vs benign)
  - BRCA1 methylation functional significance
  - Chronic ileitis etiology
  - Thyroid monitoring post-lobectomy
  - Pre-2020 medical void
  - Incomplete family history
related_analyses:
  - cancer-timeline
  - molecular-profile
  - questions-for-oncologist
  - clinical-trials
---

# Deep Clinical Analysis — Alexander Towell

## Patient Profile

- **Age**: 50 (DOB 8/4/1975)
- **Primary diagnosis**: Metastatic terminal ileum adenocarcinoma, MSS, RAS wild-type
- **Prior**: Sigmoid colon adenocarcinoma (pT4aN1a, 2021)
- **Current status**: Post-liver resection x3 (segment 2 + segments 5/8 + 4B), MRD-negative, on mFOLFOX6 alone (started Feb 2026; panitumumab held in reserve)
- **CEA**: 1.7 (Feb 5, 2026) — lowest ever recorded
- **Active medications**: Levothyroxine 125mcg, gabapentin 100mg, ferrous sulfate, vitamin D, omega-3, multivitamin, propranolol 20mg, lorazepam 0.5mg, zolpidem 5mg, cetirizine, loperamide, docusate, lidocaine patch

---

## I. The Central Diagnostic Question: One Cancer or Two?

This is the single most important unresolved question in this case.

### The evidence for **one cancer** (sigmoid primary with peritoneal/ileal metastasis):

1. **pT4a sigmoid primary (2021)** — the tumor penetrated the visceral peritoneum. This is the textbook mechanism for peritoneal seeding.
2. **No precursor lesion** in the ileal mucosa — Dr. Byrnes explicitly noted "No precursor lesion or adenoma identified in the background ileum." Small bowel adenocarcinoma arising de novo (without a precursor) is extremely rare.
3. **Bulk of tumor in perienteric soft tissue** — Dr. Byrnes: "The bulk of the tumor appears to arise in the perienteric soft tissue." This is exactly what a peritoneal implant would look like — tumor growing from the outside in, not from the mucosa out.
4. **Morphologically similar** to the sigmoid primary per Wash U pathology review.
5. **Rectovesicular pouch deposits** on PET (2024) — peritoneal carcinomatosis pattern.
6. **5 tumor deposits** in the mesentery of the ileal specimen — tumor deposits (discrete tumor nodules without identifiable lymph node architecture) are pathognomonic for peritoneal spread.

### The evidence for **two independent primaries**:

1. **2.5-year interval** between surgeries (Dec 2021 → Jul 2024)
2. Both tumors are moderately differentiated adenocarcinoma — this morphology is extremely common and doesn't prove clonal relationship
3. Dr. Byrnes offered both possibilities: "could represent a new ileal primary" vs. "spread from the prior colonic primary"

### Why this matters clinically:

- If one cancer: This is **Stage IV** (pT4a with peritoneal and liver metastases). The disease has demonstrated metastatic potential and the liver lesions are part of a continuous metastatic process. Aggressive multimodal therapy (systemic + surgical) is appropriate.
- If two cancers: The first was Stage IIIB (cured by surgery + adjuvant FOLFOX), and the second is a separate Stage IVa. The prognosis and treatment implications differ because each cancer's biology may be independent.

### The pending Guardant Tissue + RNA test may help resolve this:
If the Dec 2025 liver metastasis shares a mutational signature with the 2021 sigmoid tumor (which was MSS, triple-WT), it supports a single clonal origin. If novel driver mutations emerge, it might suggest independent evolution.

**My assessment**: The weight of evidence strongly favors **one cancer** — a sigmoid adenocarcinoma that penetrated the serosa (pT4a), seeded the peritoneum, implanted on the ileum, and later metastasized to the liver. The absence of a mucosal precursor lesion and the perienteric location of the ileal tumor are the strongest indicators.

---

## II. What the Oncology Team Is Doing Right

1. **Wash University referral** — moving from Anderson Hospital (community) to Barnes-Jewish/Siteman Cancer Center was critical. Access to Dr. Chapman (liver surgery), multidisciplinary tumor board, and advanced pathology review.

2. **Liver-directed surgery** — three liver resections (segment 2, segments 5/8, segment 4B) have been performed with curative intent. The Dec 2025 resection achieved negative margins on both specimens. This is exactly the right approach for oligometastatic CRC.

3. **Anti-EGFR correctly held in reserve** — Despite the EHR treatment plan header listing mFOLFOX6+Panitumumab, Dr. Tan's written assessment confirms the patient is on FOLFOX alone. This is **the right decision**. The New EPOC trial (Lancet Oncology) showed that adding cetuximab to perioperative chemotherapy for resectable colorectal liver metastases **worsened outcomes** — median OS 55.4 months vs. 81.0 months with chemo alone (trial stopped early). A 2025 meta-analysis confirmed: anti-EGFR benefits unresectable mCRC but harms resectable/NED patients. Panitumumab is being preserved as a potent weapon for if/when unresectable disease recurs.

4. **MRD-guided decision-making** — ordering Guardant360 and Guardant Tissue to guide adjuvant therapy decisions shows state-of-the-art practice.

5. **Bone scan** — the sclerotic left iliac bone lesion was followed up with a whole-body bone scan (May 2024). The fact it hasn't been mentioned as concerning in subsequent notes suggests it was benign.

6. **Regular surveillance** — CT and MRI alternating, CEA every 2-3 weeks during treatment, PET/CT at key decision points.

---

## III. Potential Gaps, Concerns, and Underexplored Areas

### 1. Positive Margin on First Liver Resection (May 2025)

The segment 2 resection pathology states: **"Adenocarcinoma present at cauterized resection margin. Perineural invasion identified."**

This is concerning because:
- Positive margins in liver resection are associated with higher recurrence risk
- Perineural invasion compounds this risk
- The subsequent new lesions in segments 4A/8 (detected Nov 2025) may represent incomplete clearance from this surgery rather than new metastatic events

**Question**: Was a re-resection of the segment 2 area considered? Or was the cautery margin considered adequate with planned systemic therapy?

### 2. The Indeterminate Right Suprahilar Lymph Node

Across multiple PET/CT scans:
- Aug 2024: "right hilar lymph node which measures at the upper limits of normal for size was hypermetabolic and could represent a metastasis"
- Nov 2024: "Persistent activity in the right hilar region, which is indeterminate"
- Aug 2025: "Indeterminate right suprahilar lymph node is stable in size and FDG avidity"

This has been called "indeterminate" for 18 months. While stability suggests benignity, in a patient with stage IV CRC:
- A biopsy (EBUS-guided) could resolve this definitively
- If metastatic, it would change staging and may influence treatment intensity
- If benign (reactive/granulomatous), it removes a source of ongoing surveillance anxiety

### 3. Indeterminate Lung Nodules

Two lung nodules have been stable since late 2024:
- **Right lower lobe**: 8-9mm solid nodule (stable over 14+ months)
- **Left lower lobe**: ~1cm groundglass nodule (stable, possibly post-infectious)

Dr. Tan's Feb 2026 note specifically discusses: "we again discussed the possibility that the lung nodule may represent metastatic disease vs benign process. This appear indeterminate radiologically."

- The RLL nodule is solid and in a patient with metastatic CRC — 14 months of stability is reassuring but not definitive
- At 8-9mm, it's in a gray zone — too small for reliable PET characterization, but large enough to biopsy
- **CT-guided biopsy** of the RLL nodule could determine if this is a 4th site of metastatic disease or an incidental benign finding
- This distinction matters for staging: liver-only metastases vs. liver + lung = different prognosis and potentially different treatment approach

### 4. BRCA1 Methylation — Resolved by Tempus xT (No Functional HRD)

The Guardant360 found BRCA1 promoter methylation, raising hopes of PARP inhibitor sensitivity. However, **the Tempus xT tissue + RNA analysis (July 2025) resolves this**:

- **HRD Score: 23 (threshold 50) — NOT homologous recombination deficient**
- Despite BRCA1 promoter methylation, the tumor does NOT exhibit functional HRD
- PARP inhibitor therapy is unlikely to benefit this tumor
- PD-L1 also negative across all 4 assays (<1%)
- Treatment recommendation from Tempus: cetuximab or panitumumab (anti-EGFR, consistent with Dr. Tan's plan)

**Note**: The Tempus xT data was initially missing from the database due to a parser bug — the caption format "Edited Result - FINAL" didn't match the expected regex. This was discovered during raw source file analysis (see data-gaps-report.md). The pending Guardant Tissue + RNA from the Dec 2025 liver specimen may provide updated HRD status from the more recent metastasis.

### 5. The Chronic Ileitis Question

The 2021 initial endoscopy showed normal small bowel mucosa. But later:
- An ileal tumor was found in the terminal ileum (2024)
- K63.89 (Other specified diseases of intestine) is on the problem list
- Chronic ileal inflammation can be a precursor to small bowel adenocarcinoma (as in Crohn's disease)

**Has Crohn's disease been formally ruled out?** The 2021 small bowel biopsy was normal, but Crohn's can be patchy. Given:
- The ileal tumor location (classic Crohn's-associated cancer site)
- The absence of a visible precursor adenoma
- The recurrent iron deficiency anemia pattern

A GI consultation specifically to evaluate for underlying Crohn's disease or other inflammatory bowel conditions could be informative for long-term surveillance planning.

### 6. Thyroid Follow-Up

- Right thyroid lobectomy performed Oct 2022 for TR4 nodule with rim calcifications
- PET/CT Aug 2025 showed **"diffuse persistent left hemithyroid activity — recommend evaluation with thyroid function tests"**
- TSH has been persistently elevated (6-7 range) even on levothyroxine, though 8/2025 showed improved 3.48 on 125mcg
- The persistent PET uptake in the remaining left thyroid lobe, combined with positive TPO antibodies (Hashimoto's), likely represents Hashimoto's thyroiditis — but should be confirmed not to represent thyroid malignancy given cancer history

### 7. Pre-2020 Medical Void — Implications

The patient went from age ~25 to ~46 with no medical care. During this time:
- A colon cancer likely developed from polyp → adenoma → carcinoma over 10-15 years
- Ferritin reached <1 (years of occult blood loss)
- Hashimoto's thyroiditis developed (TPO Ab 91)
- Obstructive sleep apnea went undiagnosed
- TSH was elevated but untreated
- The tumor grew to 6cm circumferential and invaded through the serosa

**For the medical record**: This should be documented as a case where lack of screening colonoscopy (recommended starting at age 45, or earlier with family history) and lack of routine bloodwork (which would have caught the progressive anemia) contributed to late-stage presentation. The family history includes "carcinoma of colon" in an unspecified relative — this may have warranted earlier screening.

### 8. Family History of Colon Cancer — Underexplored

The MEDITECH records list "Carcinoma of colon" in a family member (relation "Not Specified"). Also: father with prostate cancer, mother with COPD, sister with depressive disorder.

- **Which relative had colon cancer?** First-degree vs. second-degree dramatically changes inherited risk assessment
- **Was genetic counseling offered?** With early-onset CRC (age 46), a family history of colon cancer, and now BRCA1 methylation — genetic testing beyond somatic tumor profiling may be warranted
- Lynch syndrome has been ruled out (MSS, intact MMR), but other hereditary syndromes (familial adenomatous polyposis, MYH-associated polyposis) should be considered

---

## IV. The Positive Picture

Despite the complexity and stage IV diagnosis, multiple signals converge favorably:

1. **CEA 1.7 and falling** — lowest ever recorded, in normal range
2. **MRD-negative** on Guardant360 (<0.05% tumor fraction)
3. **Two clean liquid biopsies** 6 months apart (Tempus XF and Guardant360)
4. **Negative margins** on most recent liver resection (Dec 2025)
5. **Complete resolution** of rectovesicular pouch peritoneal deposits
6. **Ideal molecular profile** for anti-EGFR therapy (RAS-WT, left-sided)
7. **Now on the optimal regimen** — mFOLFOX6 + panitumumab
8. **Being treated at a major NCI-designated cancer center** (Siteman/Wash U)
9. **No evidence of new metastatic disease** on most recent imaging (Jan 2026)
10. **Stable lung nodules** — 14+ months without growth
11. **Good functional status** — no documented performance status decline
12. **Necrosis in liver metastases** (Dec 2025 pathology) — suggests treatment effect

## V. What to Watch For

| Signal | Frequency | Concern Trigger |
|--------|-----------|-----------------|
| CEA | Every 2-3 weeks during chemo | Any sustained rise above 3.0 |
| CT Chest | Every 3-6 months | Growth of RLL nodule above 10mm |
| MRI Liver | Every 3-4 months | Any new enhancing lesion |
| Guardant360 repeat | Every 3-6 months | Tumor fraction rising above 0.05% |
| Neuropathy assessment | Every visit | Oxaliplatin cumulative dose tracking |
| TSH | Every 3-6 months | Persistent elevation >4.5 on current dose |
| CBC | Weekly during FOLFOX | Myelosuppression (prior issue with FOLFOX) |
| Skin toxicity | Every visit | Panitumumab-associated rash (correlates with efficacy) |

---
*Generated 2026-02-15 from chartfold database (3 EHR sources)*
